The Federal Commission for the Protection against Sanitary Risks (Cofepris), warned about the identification of nine falsified batches of the real medicine Keytrude (pembrolizumab), classified as a monoclonal antibody and used to treat patients with metastatic or non-removable melanoma and lung cancer.
We recommend you: Alert for false Chinese tests to detect COVID in CDMX modules
Cofepris responded to health complaints filed by the pharmaceutical company Merck Sharp and Dohme Comercializadora S. de RL de CV, who identified irregularities in nine batches of the Keytruda product in a 100 mg/4 mL solution presentation.
Cofepris warns about counterfeit oncology drug Keytruda (pembrolizumab): the marketing and consumption of a fake product represent a health risk. 👇 https://t.co/4BdY2okxbR pic.twitter.com/VGm0OqmmG1
— COFEPRIS (@COFEPRIS) February 9, 2022
Check lot numbers
The authority asks review lot numbers to rule out any risk.
The lots T009249, S035357, S012080, T021792, LT87333, LT78236, DC68976, DE68005 and VZ01380 were identified as fake.
In some cases, secondary packaging with English text was also found, an additional inconsistency that can be identified by users and distributors.
“The consumption of any counterfeit and/or adulterated product represents a health risk for patients, since its quality and efficacy cannot be guaranteed. In case of identifying mentioned batch numbers or indicated inconsistencies, this health authority recommends suspending the use of false products immediately, “explains Cofepris in a statement.
With information from Cofepris